Systolic Heart Failure is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Systolic Heart Failure have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Systolic Heart Failure compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Systolic Heart Failure overview

Systolic heart failure is a cardiovascular disorder marked by specific features, including the enlargement of the heart’s ventricles, resulting in reduced ejection fraction, a measure of the heart’s pumping efficiency. This condition can manifest as either a chronic, long-term issue or an acute, sudden onset event. However, in both forms, a critical factor contributing to the progression of systolic heart failure is left ventricular remodeling. This process involves structural and functional changes in the left ventricle of the heart, ultimately impacting its ability to pump blood effectively. These alterations in heart shape and function lead to a vicious cycle of deteriorating cardiac performance, making left ventricular remodeling a central concern in the management and understanding of systolic heart failure.

For a complete picture of PTSR and LoA scores for drugs in Systolic Heart Failure, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.